aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
May 09, 2022 16:00 ET
|
aTyr Pharma, Inc.
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod...
aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting
April 11, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update
March 14, 2022 16:00 ET
|
aTyr Pharma, Inc.
FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022. Company ended 2021...
aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
March 08, 2022 16:35 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
November 09, 2021 08:05 ET
|
aTyr Pharma, Inc.
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data...
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
November 03, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
October 06, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
October 01, 2021 08:01 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810
May 19, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
April 14, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...